TrialSpark, a tech-enabled drug development partner involved in improving the speed, quality and innovation of clinical trials, announced yesterday that it has named and Dr Ken Somberg as its new chief medical officer and Quentin Chu as its new president and chief financial officer.
After spending 12 years at Novartis where he served as the therapeutic area head for Clinical Research, and later in Regulatory Affairs for the Transplantation and Immunology Business Unit, Somberg joined Covance Inc as CMO in 2009. Most recently, Somberg served as CMO of Nevakar Inc, focusing on developing innovative products in injectable and ophthalmic therapeutics.
Prior to joining TrialSpark, Chu was CFO at CityMD, with experience in healthcare and private equity having served at Crestview Partners and The Carlyle Group.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA